INTRODUCTION
Human blood platelets are terminally differentiated and anucleated cells, the activation of which plays a key role in normal haemostasis. A number of agonists, including thrombin, collagen, thromboxane A # , ADP, noradrenaline (epinephrine) and von Willebrand factor, are able to stimulate platelets to different degrees. Depending on the agonist, platelet activation is accompanied by shape change, aggregation and release of granule contents [1, 2] . Platelet activation involves an inside-out signalling, which activates the aggregation receptor, integrin αIIb-β3 [also called glycoprotein IIb-IIIa (GPIIb-IIIa)]. Activated αIIb-β3 links fibrinogen, which allows platelet aggregation and hence triggers an outside-in signalling. The latter event is necessary for full platelet spreading and aggregation, and effective haemostatic plug formation [3] . Outside-in signalling regulates the activation and tyrosine phosphorylation of intracellular proteins such as p125FAK (where FAK is focal adhesion kinase), p72Syk, Btk, Tec, SHIP [Src homology (SH2)-containing inositol 5h-phosphatase] and ERK2 (extracellular-signal-regulated kinase 2), and that of the β3 subunit itself [3] [4] [5] [6] [7] . The tyrosine-phosphorylated β3 subunit associates with the adaptor proteins Grb2 (growthfactor-receptor-bound protein 2) and SHC (Src-homology collagen) [7] . The tyrosine motif in the αIIb-β3 cytoplasmic domain is necessary for the outside-in signalling, and indispensable for normal mouse haemostasis [8] .
Cbl protein is the product of the c-cbl proto-oncogene, the cellular homologue of the v-cbl oncogene present in the Cas-NS-1 retrovirus which induces pre-B cell lymphomas and myeloid leukaemias [9, 10] . Cbl is an adaptor protein that is present in a wide variety of cell systems, is phosphorylated on tyrosine and serine, is associated with a number of signalling proteins, and is Abbreviations used : FAK, focal adhesion kinase; LIBS6, ligand-induced binding site 6; mAb, monoclonal antibody; NP40, Nonidet P40; PI 3-kinase : phosphoinositide (phosphatidylinositol) 3-kinase; RGDS, Arg-Gly-Asp-Ser peptide; SH, Src homology. 1 To whom correspondence should be addressed (e-mail bachelot!pharmacie.univ-paris5.fr).
Cbl phosphorylation and increased the PI 3-kinase activity associated with Cbl. Both thrombin and antibodies to αIIb-β3 induced association of Cbl with the tyrosine kinase, Syk. Experiments performed with inhibitors of tyrosine kinases indicated that both Src-family kinases and Syk contribute to phosphorylation of Cbl and its consequent association with PI 3-kinase. The results show that, following integrin αIIb-β3 engagement, Cbl is tyrosine phosphorylated, recruits PI 3-kinase to this integrin signalling pathway and possibly enhances PI 3-kinase activity, downstream of Src-family tyrosine kinases and Syk activation.
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involved in cell proliferation following activation of a number of cell systems [11] [12] [13] [14] . In a recent report [15] , using the plateletderived growth factor receptor β as a direct substrate, Cbl was shown to have ubiquitin ligase activity. For the latter activity, Cbl requires its intact SH2 and RING finger domains [15] . In platelets, the first reports on Cbl concerned its tyrosine phosphorylation during activation by thrombopoietin, and by convulxin or collagen [16, 17] . We have also shown that phosphorylation of Cbl and its association with p85\phosphoinositide 3-kinase (PI 3-kinase) were markedly increased after FcγRIIa-mediated platelet activation [18] . In a variety of cells, integrin-mediated cell activation induces tyrosine phosphorylation of Cbl. Indeed, Cbl is the major tyrosine-phosphorylated CrkL-binding protein in the megakaryoblastic cell line MO7e after stimulation through the β1 integrin [19] . In pre-B cells, Cbl is phosphorylated on tyrosine, and is associated with the p85 subunit of PI 3-kinase after ligation of the β1 integrin [20] . The transformation of fibroblasts by oncogenic forms of Cbl induces constitutive activation of integrin-dependent signalling events, suggesting an important role for Cbl in this pathway [21] . In macrophages, tyrosine phosphorylation of Cbl is gradual and persistent during integrinmediated cell activation, and allows the association of Cbl with active proteins (Src, Fgr, Lyn and PI 3-kinase) and the translocation of Cbl to the plasma membrane [22, 23] . To our knowledge, the engagement of Cbl in platelet integrin signalling pathways has not yet been studied.
In the present work, we demonstrate that, downstream of αIIb-β3 integrin engagement, there is tyrosine phosphorylation of Cbl and an increase in Cbl-associated PI 3-kinase activity. Cbl phosphorylation and the association of Cbl with PI 3-kinase were dependent on the binding of fibrinogen to αIIb-β3 integrin after platelet activation by thrombin, but not after direct activation through αIIb-β3 by monoclonal antibodies. αIIb-β3 integrin engagement also led to the association of Cbl with the tyrosine kinase, Syk.
EXPERIMENTAL

Antibodies and reagents
Anti-Cbl polyclonal antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). The anti-FcγRII monoclonal antibody (mAb) IV.3 was from Medarex (West Lebanon, NH, U.S.A.). Anti-LIBS6 (ligand-induced binding site 6) and P256 activating mAbs were kindly donated by Professor M. H. Ginsberg (The Scripps Research Institute, La Jolla, CA, U.S.A.) and Dr N. Hogg (Imperial Cancer Research Fund, London, U.K.) respectively. Sheep anti-mouse horseradish-peroxidaselabelled antibody was from Amersham (Little Chalfont, Bucks., U.K.). Irrelevant mAbs and polyclonal antibodies were from Immunotech (Marseille, France). Anti-p85\PI 3-kinase antiserum was from Upstate Biotechnology Inc. (Lake Placid, NY, U.S.A.). Goat anti-rabbit horseradish peroxidase-labelled antibody was from Bio-Rad (Ivry Sur Seine, France). The antiphosphotyrosine monoclonal antibodies PY20 and 4G10 were from Transduction Laboratories (Lexington, KY, U.S.A.) and Upstate Biotechnology respectively. Human thrombin was from Diagnostica-STAGO (Asnie' re, France). The Src-family kinase inhibitor PP2 was from Calbiochem (San Diego, CA, U.S.A.). Phosphatidylinositol, Protein A-Sepharose, leupeptin, aprotinin, piceatannol, PMSF, metrizamide and isopropyl β--thiogalactoside were from Sigma (Saint Quentin Fallavier, France).
Platelet preparation
Human platelets were isolated from fresh platelet concentrates obtained from healthy donors who had not taken aspirin for at least 1 week. The concentrates were centrifuged at room temperature for 15 min at 130 g, and then subjected to a washing process as described previously [24] . Briefly, platelets were isolated on a metrizamide gradient, collected and resuspended in 10 mM Hepes buffer, pH 7.4, containing 140 mM NaCl, 5 mM NaHCO $ , 0.5 mM MgCl # , 3 mM KCl and 10 mM glucose. The platelet concentration was adjusted to 10*\ml for immunoprecipitation studies. CaCl # (1 mM) was added 10 min before platelet stimulation.
Platelet activation
Platelets were stimulated with P256 or anti-LIBS6 antibodies (10 µg\ml) or with human thrombin (1 unit\ml) at 37 mC in an aggregometer (Coulter, Havertown, PA, U.S.A.) under constant stirring (1100 rev.\min), in the presence or in the absence of ArgGly-Asp-Ser peptide (RGDS ; 100 µg\ml) to inhibit fibrinogen binding to αIIb-β3 and platelet aggregation. RGDS was also tested at 400 µg\ml, and gave the same results as at 100 µg\ml. Fibrinogen (200 µg\ml) was added to platelets activated by mAbs against αIIb-β3. In order to inhibit the Fc receptor signalling pathway, platelets were preincubated for 1 min at 37 mC with mAb IV.3 (10 µg\ml) before the addition of either P256 or anti-LIBS6 antibodies.
Immunoprecipitation and Western blot analysis
Immunoprecipitation studies and Western blot analysis were performed as described previously [18] . The membranes were stripped to remove the bound antibody by incubation in a solution containing 2 % SDS, 62.5 mM Tris, pH 6.8, and 100 mM 2-mercaptoethanol for 40 min at 60 mC. After extensive washing, the membranes were re-probed. To control for the recovery of the immunoprecipitated Cbl protein, all membranes were reprobed with the anti-Cbl antibody.
Platelet cytoskeleton analysis
The Nonidet P40 (NP40)-insoluble fraction (cytoskeleton) was isolated as described previously [18] , and washed three times with NP40-containing buffer (1 % NP40, 50 mM Tris, 50 mM NaCl, 5 µg\ml leupeptin, 5 µg\ml aprotinin, 1 mM EGTA, 1 mM Na $ VO % and 1 mM PMSF). The cytoskeletal fraction was solubilized in an SDS solution (10 % SDS and 5 mM EDTA), and 1 vol. of 4i concentrated Laemmli sample buffer was added to 4 vol. of solubilized cytoskeletal fraction, with 5 % 2-mercaptoethanol. The samples were subjected to SDS\PAGE and Western blot analysis.
Measurement of PI 3-kinase activity
The measurement of PI 3-kinase activity was performed using immunoprecipitates obtained as described above, with additional extensive washing at 4 mC. Immunoprecipitates were washed twice in 20 mM Hepes containing 10 % glycerol, 1 % NP40, 150 mM NaCl and 1 mM vanadate ; twice in PBS containing 1 % NP40 and 100 µM vanadate ; twice in 0.5 M LiCl\0.1 M Tris, pH 7.5 ; and twice in 0.1 M NaCl\1 mM EDTA\20 mM Tris, pH 7.5. The last wash was performed in a kinase buffer (20 mM Tris, pH 7.5, 100 mM NaCl and 0.5 mM EGTA) containing 0.2 mM adenosine to inhibit PI 4-kinase activity. The assay was performed in the kinase buffer by adding 10 µg of sonicated phosphatidylinositol (resuspended in 10 mM Hepes and 1 mM EGTA, pH 7.5), 100 µM ATP, 25 mM MgCl # and 10 µCi of [γ-$#P]ATP to the immunoprecipitates, in a final volume of 50 µl. The reaction was stopped after incubation for 10 min at room temperature by the addition of 150 µl of a stop solution containing chloroform\methanol\11.6 M HCl (50 : 100 : 1, by vol.). The lipids were extracted by the addition of 100 µl of chloroform. The extract was washed with 200 µl of methanol\1 M HCl (1 : 1, v\v). The lipids were resolved using chloroform\methanol\ 28 % ammonium hydroxide\water (86 : 76 : 10 : 14, by vol.) on silica gel TLC plates precoated with potassium oxalate. The reaction product migrated to the same position as that produced by using a recombinant purified PI 3-kinase (a gift from Professor L. C. Cantley, Beth Israel Hospital, Boston, MA, U.S.A.) with the phosphatidylinositol substrate. This reaction product ([γ-$#P]-phosphatidylinositol 3-phosphate) was visualized by autoradiography and measured by liquid scintillation counting.
RESULTS
Cbl is tyrosine phosphorylated during platelet activation through αIIb-β 3 integrin
In order to determine the involvement of Cbl in αIIb-β3-integrinmediated signal transduction, we first investigated the state of Cbl tyrosine phosphorylation. To specifically study the outsidein signalling, we used two mAbs that activate platelets directly via αIIb-β3 integrin. The two mAbs, P256 and anti-LIBS6, were used in the presence of IV.3, an anti-FcγRII mAb which inhibits the binding of the IgG Fc domain to FcγRII.
Cbl was immunoprecipitated and analysed by Western blotting with anti-phosphotyrosine antibodies. In resting platelets, Cbl was not tyrosine phosphorylated. Cbl phosphorylation was observed after 1 min of platelet activation by P256 mAb, peaked 
Effects of fibrinogen binding to αIIb-β 3 integrin and outside-in signalling on Cbl tyrosine phosphorylation
The major role of the αIIb-β3 integrin is to mediate platelet aggregation by linking fibrinogen. We therefore investigated whether the Cbl phosphorylation that we have observed previously in thrombin-activated platelets [18] is a consequence of fibrinogen binding to αIIb-β3. For this purpose, we studied platelet activation by thrombin in the presence or absence of RGDS, which inhibits fibrinogen binding to activated αIIb-β3 integrin, and hence platelet aggregation and outside-in signalling. In the presence of RGDS, thrombin-induced Cbl tyrosine phosphorylation was totally inhibited (Figure 2a) . In contrast, after activation by mAbs against αIIb-β3 integrin (P256 or anti-LIBS6) in the presence of IV.3, Cbl phosphorylation was unmodified by the presence of RGDS for at least 10 min (Figures  2b and 2c) , although platelet aggregation was totally abolished (results not shown). A small decrease in Cbl phosphorylation was observed, however, in the presence of RGDS after 20 min of platelet activation by anti-LIBS6 or P256 mAbs (Figures 2b and  2c ). This suggests that fibrinogen binding contributes to Cbl phosphorylation at later times of platelet activation induced by mAbs against αIIb-β3. In thrombin-activated platelets under non-stirred conditions, the profile of Cbl phosphorylation was similar to that obtained with stirring (results not shown). The latter result suggests that fibrinogen binding to αIIb-β3 is required for Cbl phosphorylation, but that platelet aggregation is not. During thrombin receptor engagement, Cbl was involved in the
Figure 2 Role of αIIb-β 3 integrin engagement in thrombin-induced tyrosine phosphorylation of Cbl
Platelets were activated either by thrombin (1 unit/ml) (a), or by the anti-αIIb-β3 mAbs (10 µg/ml) anti-LIBS6 (b) or P256 (c) in the presence of IV.3 (10 µg/ml), and in the presence or in the absence of RGDS (100 µg/ml), for the indicated times (min). Platelets were then lysed by NP40-containing buffer and Cbl was immunoprecipitated (IP). The immunoprecipitates were subjected to SDS/PAGE, followed by anti-phosphotyrosine (anti-PY) immunoblotting. The same membranes were re-probed with anti-Cbl antibody. Results are representative of three experiments.
outside-in signalling (post-occupancy events) following fibrinogen binding to αIIb-β3, but not in early events of the insideout signalling which activates αIIb-β3 integrin. The binding of the activating antibodies to αIIb-β3 is, by itself, able to induce the outside-in signalling. Hence Cbl was phosphorylated independently of fibrinogen binding when platelet activation was mediated by mAbs to αIIb-β3 integrin.
Src-family tyrosine kinases and Syk participate in Cbl phosphorylation in platelets
In order to investigate the involvement of tyrosine kinases in Cbl phosphorylation, we used a Src-family kinase inhibitor, PP2, and the Syk kinase inhibitor, piceatannol. In the concentration range 10-30 µg\ml, piceatannol strongly inhibits Syk, but not Srcfamily kinases [25] . Our results show that, in thrombin-activated platelets (Figure 3a) , Cbl phosphorylation was slightly decreased in the presence of 50 nM PP2, but was strongly inhibited by 5 µg\ml piceatannol and was totally abolished by 20 µg\ml piceatannol or by PP2 at 500 nM or 1 µM. When platelets were activated by mAb P256 (Figure 3b) , a low dose of piceatannol (5 µg\ml) did not affect Cbl tyrosine phosphorylation. Cbl phosphorylation was decreased in the presence of 50 nM PP2, was strongly inhibited by 500 nM PP2 or 20 µg\ml piceatannol, and was totally abolished by 1 µM PP2. These data indicate that
Figure 3 Involvement of Syk and Src-family tyrosine kinases in Cbl phosphorylation
Platelets were incubated for 15 min at 37 mC with different concentrations of the inhibitors piceatannol (Pic) or PP2. Platelets were activated for 5 min by either thrombin (1 unit/ml) (a) or P256 mAb (10 µg/ml) (b). After cell lysis by NP40 buffer, Cbl was immunoprecipitated (IP). Cbl immunoprecipitates were subjected to SDS/PAGE and Western blot analysis using antiphosphotyrosine (anti-PY) antibodies. The same membranes were then re-probed with anti-Cbl antibody. Results are representative of three experiments.
both Src-family and Syk kinases contribute to Cbl tyrosine phosphorylation in platelets activated through αIIb-β3.
Association of Cbl with the actin cytoskeleton
Next we analysed the translocation of Cbl to the platelet actin cytoskeleton. In resting platelets, Cbl was present only in the NP40-soluble fraction, and was absent from the NP40-insoluble fraction corresponding to the actin cytoskeleton (Figures 4a and  4b) . Following platelet activation by thrombin or mAbs to αIIb-β3, the quantity of Cbl in the cytoskeletal fraction increased over time (Figures 4a and 4b, upper panels) . This was accompanied by a parallel decrease in the amount of Cbl in the soluble fraction (Figures 4a and 4b, lower panels) . Interestingly, RGDS did not modify the profile of Cbl association with the actin cytoskeleton in platelets activated by thrombin or mAbs (Figures 4a and 4b) . In contrast, the tyrosine kinase inhibitors piceatannol and tyrphostin B56 partially inhibited the association of Cbl with the actin cytoskeleton induced by mAb P256 (Figure 4c ). The tyrosine phosphatase inhibitor phenylarsine oxide increased Cbl translocation (Figure 4c ). These results indicate that Cbl is translocated in the cytoskeleton during platelet activation, independently of fibrinogen binding and platelet aggregation, and this translocation depends in part on the activation of tyrosine kinases.
Cbl associates with PI 3-kinase following αIIb-β 3 integrin engagement
PI 3-kinase is involved in platelet signalling mediated by αIIb-β3 integrin [26] [27] [28] [29] . Since p85\PI 3-kinases are known to be regulated by the association of p85 with phosphotyrosine motifs on other proteins [30] , we investigated whether Cbl could be a candidate protein to stimulate the PI 3-kinase activity following αIIb-β3 integrin engagement and platelet aggregation. Our results showed that the p85 subunit of PI 3-kinase was co-immuno-
Figure 4 Translocation of Cbl to the actin cytoskeleton of activated platelets
Platelets were activated in the presence or absence of 100 µg/ml RGDS by 1 unit/ml thrombin (a) or 10 µg/ml IV.3jP256 mAbs (b) for different times (min), as indicated. After cell lysis by NP40-containing buffer, the NP40-insoluble fraction (cytoskeleton) was separated from the soluble fraction. The samples from both fractions were subjected to SDS/PAGE and Western blot analysis by anti-Cbl antibody. The cytoskeleton of platelets activated by 10 µg/ml IV.3jP256 mAbs in the presence of 20 µg/ml piceatannol, 100 µM tyrphostin B56 or 10 µM phenylarsine oxide (PAO) was separated and probed with anti-Cbl antibody (c). Results are representative of three experiments. precipitated with Cbl between 2 and 10 min of platelet activation by thrombin (Figure 5a ), although this association was low compared with that induced after Fc receptor engagement [18] . The Cbl-PI 3-kinase association was decreased at 20 min of platelet activation, and depended on fibrinogen binding to αIIb-β3, since RGDS inhibited the transient Cbl-PI 3-kinase interaction (Figure 5a ). We have also observed an association of Cbl with PI 3-kinase in thrombin-activated platelets under nonstirred conditions (results not shown). In platelets activated by
Figure 5 Association of Cbl with p85/PI 3-kinase in αIIb-β 3-mediated platelet activation
The nitrocellulose membranes corresponding to Figure 2 were re-probed with antibody against p85/PI 3-kinase. 
Figure 6 Measurement of PI 3-kinase activity associated with Cbl
Platelets were activated for 5 min by thrombin, IV.3jP256 mAbs or IV.3janti-LIBS6 mAbs in the presence or in the absence of RGDS. Lysates were subjected to anti-Cbl immunoprecipitation. A control immunoprecipitation was performed using non-immune antibody. After extensive washing of the immunoprecipitates, the PI 3-kinase assay was performed. Data are meanspS.E.M. of three independent experiments. the anti-LIBS6 mAb, the association between Cbl and PI 3-kinase was stable up to 20 min, and was unaffected by RGDS (Figure 5b ). The P256 mAb induced a profile for the Cbl-PI 3-kinase association similar to that induced by anti-LIBS6 (results not shown).
Next we measured the PI 3-kinase activity in Cbl immunoprecipitates. In platelets activated by either thrombin or mAbs to αIIb-β3, the PI 3-kinase activity in Cbl immunoprecipitates increased by 3-5 times over the basal activity observed in the resting state ( Figure 6 ). In thrombin-activated platelets the PI 3-kinase activity associated with Cbl was strongly inhibited by the presence of RGDS, whereas this activity was not affected by RGDS in platelets activated by mAbs to αIIb-β3 (IV.3janti-LIBS6 or IV.3jP256) ( Figure 6 ). Given the correlation observed between Cbl phosphorylation (Figure 2a ) and its association with p85\PI 3-kinase ( Figures 5 and 6 ), our results suggest that the association of Cbl with PI 3-kinase depends on Cbl tyrosine phosphorylation. In thrombin-activated platelets, the Cbl association with PI 3-kinase was due mainly to fibrinogen binding to αIIb-β3 and the subsequent outside-in signalling, whereas in platelets activated by mAbs to αIIb-β3 integrin it was independent of fibrinogen binding to αIIb-β3.
To establish whether phosphorylation of Cbl is required for its association with PI 3-kinase, we studied the effects of the inhibitors PP2 and piceatannol on the Cbl-associated PI 3-kinase activity. The increased PI 3-kinase activity in Cbl immunoprecipitates observed after platelet activation by thrombin was inhibited by 67p14 % in the presence of 50 nM PP2 (Figure 7a , bar 4), and was totally inhibited by 500 nM PP2 or by 20 µg\ml piceatannol (Figure 7a, bars 5 and 7) . This activity was inhibited by 92p13 % in the presence of 5 µg\ml piceatannol (Figure 7a , bar 6). In platelets activated by mAb P256 (Figure 7b) , the increased PI 3-kinase activity associated with Cbl immunoprecipitates was inhibited by 68p13 % and 68p6 % by low concentrations of PP2 (50 nM) and of piceatannol (5 µg\ml) respectively (Figure 7b , bars 4 and 6). This activity was inhibited by 85p10 % in the presence of 500 nM PP2 (bar 5), and was totally abolished by 20 µg\ml piceatannol (bar 7). The decrease
Figure 7 Effects of inhibition of Src-family kinases and Syk on the association of PI 3-kinase with Cbl
Platelets were incubated with PP2 or piceatannol as in Figure 3 . Activation was performed for 5 min either with thrombin (1 unit/ml) (a) or with IV.3jP256 mAbs (10 µg/ml) (b). Bars : 2, resting platelets ; 3, activated platelets in the absence of inhibitors ; 4-7, activated platelets in the presence of inhibitors : 50 nM PP2 (4), 500 nM PP2 (5), 5 µg/ml piceatannol (6) or 20 µg/ml piceatannol (7). After cell lysis by NP40-containing buffer, Cbl was immunoprecipitated (bars 2-7). A control immunoprecipitation was performed with non-immune antibody (bar 1). PI 3-kinase activity was measured in each immunoprecipitate. Data are meanspS.E.M from three independent experiments. The insets show Western blots with anti-p85/PI 3-kinase performed on Cbl immunoprecipitates obtained using the same conditions. in PI 3-kinase activity associated with Cbl corresponded to the decrease in the amount of p85\PI 3-kinase present in Cbl immunoprecipitates, as shown by Western blots (insets of Figures  7a and 7b) . The results favour a role for tyrosine-phosphorylated Cbl in the positive regulation of PI 3-kinase activity, downstream of the activation of Src-family tyrosine kinases and Syk.
Association of Cbl with Syk in activated platelets
Cbl is known to negatively regulate Syk tyrosine kinase activity in mast cells and COS-7 cells [31, 32] . We asked whether Cbl associates with Syk in platelets. For this purpose, we tested for the presence of Syk in Cbl immunoprecipitates. In resting platelets, Syk was hardly detectable in Cbl immunoprecipitates, whereas during platelet activation Cbl became associated with Syk. In thrombin-activated platelets, the Syk-Cbl association was observed at 2 min, reached a plateau between 5 and 10 min, and decreased thereafter, although it was still detectable at 20 min (Figure 8a ). In the presence of RGDS, the thrombininduced Cbl-Syk association was inhibited at 5 min and 10 min (although not totally), and was unchanged at 2 min and at 20 min (Figure 8a) . Direct activation through αIIb-β3 by mAbs 
Figure 9 Association of Syk with the β 3 subunit of αIIb-β 3 integrin
Washed platelets were activated for 2 min by thrombin (1 unit/ml) in the presence or absence of RGDS (100 µg/ml), and lysed by NP40-containing buffer. αIIb-β3 was then immunoprecipitated (IP) from the NP40-soluble fraction, and a control immunoprecipitation was performed using non-immune antibody (NI). The samples were subjected to SDS/PAGE and Western blot analysis using anti-Syk and anti-β3 antibodies. Results are representative of three experiments.
induced the association of Cbl with Syk, which peaked at 1-10 min and had decreased by 20 min (Figure 8b ). In contrast with thrombin, however, the presence of RGDS did not affect the Cbl-Syk association. These results demonstrate the association of Cbl with Syk during platelet activation through αIIb-β3. This association was partly dependent on αIIb-β3 engagement in thrombin-activated platelets.
In order to determine if Syk associates with the β3 subunit of αIIb-β3 integrin, we searched for its presence in the immunoprecipitates of αIIb-β3. With resting platelets, no association of Syk with αIIb-β3 was observed. After activation by thrombin, Syk became associated with αIIb-β3, and this association was partly inhibited by the presence of RGDS (Figure 9 ). Moreover, we immunoprecipitated the αIIb and β3 subunits separately, and found that only the β3 subunit was tyrosine phosphorylated and associated with Syk in thrombin-activated platelets (results not shown). These results suggest that Syk could initiate the signalling that occurs following the engagement of αIIb-β3 integrin.
DISCUSSION
The αIIb-β3 integrin is one of the most abundant molecules present at the surface of the platelet membrane. It binds several adhesive proteins, including fibrinogen, fibronectin, vitronectin and von Willebrand factor. The binding of such ligands induces post-occupancy events that participate in platelet activation [3] . The present results help to define further the αIIb-β3 integrin pathway in platelets, and demonstrate the involvement of Cbl, PI 3-kinase and Syk in this outside-in signalling.
The involvement of Cbl in the signal transduction mediated by the platelet integrin αIIb-β3 was studied using mAbs that activate αIIb-β3 directly, and by using thrombin. In thrombin-activated platelets, phosphorylation of Cbl depended on fibrinogen binding. Indeed, in the presence of RGDS to inhibit fibrinogen binding to αIIb-β3 and platelet aggregation, thrombin-induced Cbl phosphorylation was totally inhibited. Previous reports described the regulation of protein tyrosine phosphorylation by αIIb-β3 in thrombin-activated platelets [3] . After platelet activation by different agonists, the outside-in signalling subsequent to fibrinogen binding to αIIb-β3 increases platelet activation through the phosphorylation of a number of proteins. Cbl appears to be one of these proteins. It is known that the anti-LIBS6 and P256 mAbs bypass the inside-out signalling by direct binding to αIIb-β3 integrin, which initiates the outside-in signalling [33] . We therefore used these mAbs to activate αIIb-β3 directly and to study this integrin signalling pathway, with a special focus on the involvement of Cbl. Under these conditions, Cbl was phosphorylated independently of fibrinogen binding to αIIb-β3.
Cbl was translocated to the cytoskeleton independently of fibrinogen binding, since RGDS did not affect this translocation during platelet activation by thrombin or by anti-αIIb-β3 mAbs. The amount of tyrosine-phosphorylated proteins observed in the cytoskeletal fractions from thrombin-activated platelets decreased in the presence of RGDS (results not shown). Although the phosphorylation of Cbl in the cytoskeleton of thrombinactivated platelets in the presence of RGDS was not analysed specifically, the phosphorylation of proteins of approx. 120 kDa decreased (results not shown), suggesting that Cbl translocation was not dependent on its own phosphorylation. Tyrosine kinase inhibitors, such as tyrphostin B56 and piceatannol, delayed the Cbl translocation, indicating that tyrosine kinases participate in cytoskeletal reorganization. Thus in activated, non-aggregated platelets, Cbl is translocated to the cytoskeleton in a similar manner to many signalling proteins such as Src, Fyn and Lyn [34] [35] [36] . The association of Cbl with the cytoskeleton during platelet activation could contribute to the reorganization of the actin cytoskeleton, as demonstrated recently in fibroblasts, in which Cbl regulates the formation of actin lamellae, lamellipodia and membrane ruffles [37] .
With the aim of understanding the mechanism by which the adaptor protein Cbl could be involved in the outside-in signalling, we searched for an association of this protein with signalling enzymes involved in the αIIb-β3 pathway. The involvement of PI 3-kinase in the αIIb-β3 signalling pathway is now well established [26] [27] [28] [29] . Our results showed that Cbl-associated PI 3-kinase activity was increased in activated platelets. The association of Cbl with PI 3-kinase was dependent on fibrinogen binding to αIIb-β3 in thrombin-activated platelets, but not in platelets activated by mAbs to αIIb-β3. Notably, during platelet activation through the Fc receptor, Cbl phosphorylation and its association with PI 3-kinase were independent of fibrinogen binding (results not shown). Thus we demonstrated that, in platelets, Cbl is involved in two signalling pathways : that of the Fc receptor [18] , and the outside-in signalling through αIIb-β3 (the present study). Moreover, it has been shown that Cbl is tyrosine phosphorylated in platelets activated by thrombopoietin, convulxin and collagen, but the involvement of αIIb-β3 engagement in this phenomenon was not investigated in these reports [16, 17] . In the present study, the association of Cbl with PI 3-kinase paralleled the level of Cbl phosphorylation. Altogether, the data are in favour of positive regulation of PI 3-kinase activity by Cbl in platelets, as in other cell types [38, 39] . PI 3-kinase plays a role in the maintenance of the active state of αIIb-β3 during platelet activation by thombin [27, 40] . Kovacsovics et al. [27] and our own results (A. Saci, F. Rendu and C. Bachelot-Loza, unpublished work) demonstrate that wortmannin (an inhibitor of PI 3-kinase activity) inhibits platelet aggregation induced by mAbs to αIIb-β3. Zhang et al. [29] described the stimulation of a C2-domain-containing PI 3-kinase isoform downstream of the αIIb-β3 integrin. This PI 3-kinase isoform has no p85 regulatory subunit that can associate with phosphotyrosine proteins, and its proline-rich sequences cannot associate with Cbl, since this latter protein does not contain an SH3 domain. Thus, in the present study, the PI 3-kinase activity measured in anti-Cbl immunoprecipitates was most probably that of p85\PI 3-kinase, i.e. the type I PI 3-kinase. Finally, considering our results and those of Zhang et al. [29] , it appears that at least two types of PI 3-kinases are activated after αIIb-β3 integrin engagement, and that intact PI 3-kinase activity is necessary for this integrin pathway.
Among other signalling partners of Cbl, Src and Syk are two important kinases in platelet activation. We were unable to detect an association between Cbl and Src. In contrast, we showed that Cbl was associated with Syk in activated platelets. In the presence of RGDS, the association of Cbl with Syk was partly inhibited in platelets activated by thrombin, but was unaffected during activation by P256 or anti-LIBS6 mAbs. Three different types of interaction could occur in the association of Cbl with Syk in platelets. First, the SH2 domain of Cbl (recently described in the N-terminal region of Cbl [41] ) could associate with the phosphotyrosine residues of Syk. This proposal is supported by the observations that during activation by thrombin : (i) in the presence of RGDS, Cbl was associated with Syk, although Cbl was not phosphorylated, and (ii) Syk tyrosine phosphorylation was partly independent of fibrinogen binding [42] . Secondly, the phosphotyrosine residues of Cbl could associate with the Syk SH2 domain. Indeed, after 1 min of platelet activation by F(ab)h2 fragments of P256 mAbs, Syk is not phosphorylated [43] , whereas Cbl is tyrosine phosphorylated and associated with Syk for up to 20 min (the present results). Also, during platelet activation by thrombin in the presence of RGDS, Cbl phosphorylation was inhibited and its association with Syk decreased at 5 and 10 min. In this regard, Cbl consensus sequences containing phosphotyrosine residues were proposed to associate with the C-terminal SH2 domain of Syk [44, 45] . Thirdly, we cannot exclude the possibility that other proteins that interact with Syk and Cbl could mediate the Cbl-Syk association in a multimolecular complex. The Syk-Cbl association could contribute to the negative regulation of Syk activity by phosphorylated Cbl in platelets, as observed in mast cells and COS-7 cells [31, 32] .
Members of the Src family and Syk kinases are involved in the tyrosine phosphorylation of Cbl in osteoclasts, COS-7 cells, fibroblasts and macrophages [12] . Moreover, recent data from COS-7 cells indicate that Cbl phosphorylation occurs downstream of a novel activated Syk\Vav pathway [46] . In activated platelets, both piceatannol and PP2 inhibited Cbl phosphorylation and Cbl-associated PI 3-kinase activity. With a low concentration of PP2 (50 nM) the inhibition was partial, suggesting that Syk could compensate for the inhibited Srcfamily kinases. Similarly, a low dose of piceatannol was unable to significantly inhibit Cbl phosphorylation in platelets activated by anti-αIIb-β3 mAbs. Low doses of piceatannol may only partly inhibit Syk activity, as shown previously in ex i o experiments [25] . Src-family kinases could also compensate for the inhibition of Syk. Finally, we cannot exclude the possibility that other kinases could be partly inhibited by piceatannol. For example, piceatannol inhibits FAK in an isolated system [47] , but this inhibition has not been confirmed in a cell system. The stronger inhibitory effects of piceatannol on Cbl phosphorylation during platelet activation by thrombin than during activation by mAbs to αIIb-β3 could be due to the involvement of Syk in the insideout signalling. Indeed, during thrombin receptor engagement, inhibition of Syk decreases the activation of αIIb-β3, and consequently decreases fibrinogen binding and inhibits the outside-in signalling [47] . Our data suggest that both Src-family tyrosine kinases and Syk participate in the phosphorylation of Cbl and hence contribute to the association of Cbl with PI 3-kinase, downstream of activated αIIb-β3.
Other molecular interactions could occur downstream of activated αIIb-β3 integrin. We found that Syk associated with Src after platelet activation by thrombin, and that this association was partly inhibited by RGDS (results not shown). In the same conditions, Syk associated with the β3 subunit of αIIb-β3 integrin, whereas we could not detect any association of Src with αIIb-β3 (results not shown). Taken together, we propose the following sequential chain of events : engagement of platelet αIIb-β3 activates Syk and Src-family kinases, which phosphorylate Cbl and promote the association of the latter with p85\PI 3-kinase, and hence PI 3-kinase activation by Cbl. This model is in keeping with a recent study in B cells which demonstrated that Cbl increases PI 3-kinase activity, dependent in part on its phosphorylation by activated Syk [39] .
In conclusion, the present results demonstrate that Cbl is involved in platelet αIIb-β3 signalling pathway by recruiting PI 3-kinase downstream of Src-family kinases and Syk. Hence Cbl could positively regulate PI 3-kinase activity. Further studies are required to determine how the αIIb-β3-mediated outside-in signalling is necessary for full platelet spreading and aggregation, and effective haemostatic plug formation.
